AVI BioPharma, Inc.
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com
Sarepta is currently seeking Vice-President, Research for a newly-created role to assume operational responsibility in areas summarized below, build and lead new integrated departments encompassing functions essential to all aspects of drug discovery to support research needs in our rapidly growing organization. In this role the VP of Research will report to the Chief Scientific Officer and will oversee an operational team developing differentiated antisense therapeutics. The team managed by the VP of Research will provide internal expertise in Chemistry, Molecular Biology, Biochemistry, Cellular Immunology/Biology, and In-vivo Pharmacology to discover and advance therapeutic candidates into clinical development. This group will also be charged with assay development utilizing protein and cell line engineering and in-vitro analytics in support of drug discovery under non-GLP conditions and Translational development under GLP compliant conditions. In close collaboration with Toxicology, DMPK, Translational development and CMC teams, this leader will ensure the seamless transition of candidate molecules from discovery into development.
Primary Responsibilities Include:
Reports to CSO and manages a team of scientists focused on developing a portfolio of precision medicine based RNA therapeutics for Sarepta’s core therapeutic areas in neuromuscular disease;
Establishes a professional tracking system for research assets and programs, and provides updates to Sarepta’s senior leaders on the research portfolio, resource allocation, and timelines.
Establishes or provides access to all the necessary competencies to advance molecules from hit-finding to lead optimization to candidate/backup selection and IND.
Provides leadership, strategic oversight, resource management, and organizational framework to ensure timely achievement of pipeline goals.
Identifies, supports and manages talent; provides ‘real-time’ feedback to direct reports for performance management and career development.
Is current with advances in the scientific literature and specifically in antisense therapeutic methodologies, including consulting with key opinion leaders.
Takes direct responsibility for Research goal-setting, budget administration, and other administrative functions.
Professionally represents the organization in collaborations, partnership discussions, and external relationships and conferences.
Protects intellectual property and contributes to value generation evidenced by high quality patents, presentations and publications.
Operational oversight and management of ongoing efforts in discovery research encompassing new lead discovery, lead optimization, and in-vivo pharmacology supporting target validation to IND enabling activities in progress in Chemistry and Biology;
Build new and lead existing departments enabling capabilities in Nucleic acid & Medicinal Chemistry, Biochemistry (protein purification, quantification, kinetic studies of biomolecular interactions) Molecular Biology (encompassing protein expression to bioinformatics), Cell Biology/Cellular Immunology (assay development in support of target validation) and In-vivo Pharmacology;
Establish and instill principles of scientific rigor and excellence in the drug development process throughout the research organization;
Manage communications and build collaborative relationships with key stakeholders and opinion leaders both internally and externally, including for example Pre-clinical and Clinical Development, executive management, external CROs/vendors, scientific advisory board, and clinical investigators.
Serve as a mentor to other members of the research staff and foster a culture of scientific excellence and cross-functional collaboration.
Education and Skills Requirements:
Advanced degree (Ph.D., M.D., or MD/PhD) in life sciences, with a minimum of 15 years’ experience in drug development, including at-least 10 yrs. of leadership & management experience in the biopharmaceutical industry;
Demonstrated ability to manage high performing, productive team(s).
The desired candidate will have experience covering a broad range of therapeutic modalities and disease indications, with a sound understanding of the fundamental principles underlying drug development ranging from PK/PD relationships, to clinical translatability of preclinical biomarkers of target engagement;
The preferred candidate will have experience with oligonucleotide therapeutics with a track record of expertise in neuromuscular disease;
The preferred candidate will possess requisite skills, first-hand experience, and deep understanding of methods covering a broad range of research techniques.
Demonstrated excellence in teamwork and effective collaboration; ability to manage and deliver on multiple objectives under aggressive timelines, balance resources and priorities to achieve objectives, possess outstanding oral and written communication skills, and contribute solutions to challenging research and translational development questions.
Candidates must be authorized to work in the U.S.
Sarepta Therapeutics offers a competitive compensation and benefit package.
Sarepta Therapeutics is an Equal Opportunity/Affirmative Action employer and participates in e-Verify.
Cambridge, Massachusetts, United States
AVI BioPharma, Inc.
Website : http://www.avibio.com/
AVI BioPharma is a biopharmaceutical company developing drugs to treat life threatening diseases using its patented third generation antisense technology. We have completed eleven clinical trials with our NeuGene® antisense drugs in more than 300 subjects addressing cardiovascular restenosis, infectious disease, cancer, polycystic kidney disease and drug metabolism. In clinical studies, our novel antisense drugs have been well tolerated and have met efficacy endpoints. We are focusing further clinical development on cardiovascular and infectious disease indications. Our most advanced cardiovascular program is for restenosis where we have completed Phase II trials evaluating our drug, Resten NG®. We are currently evaluating a systemic formulation of this drug in additional Phase II studies in Europe.